Contents

List of Contributors ix

Chapter 1: Toxicity of Anticancer Drugs to Humans: A Unique Opportunity to Study Human Toxicology 1
Garth Powis

Cancer, a Worldwide Problem 1
Drugs Used to Treat Cancer 2
Origins of Modern Cancer Chemotherapy 2
Toxicity and Cancer Chemotherapy 3
Combinations of Anticancer Drugs 4
Toxicities of Anticancer Drugs 5
Factors Affecting Cancer Drug Toxicity 5
The Future 7
References 8

Chapter 2: Prediction of Human Toxicity of New Antineoplastic Drugs from Studies in Animals 10
Charles K. Grieshaber

Evolution of Procedures for Preliminary Toxicologic Evaluation of Experimental Cancer Chemotherapeutic Agents in Animals 12
Animal Toxicology in the Prediction of Antineoplastic Drug Toxicity in Humans 14
Guidelines for Preclinical Animal Pharmacology and Toxicology Studies for New Drugs Designed to Treat Human Diseases of Fatal Outcome 20
References 24

Chapter 3: Second Tumors After Treatment With Anticancer Drugs 28
Charles B. Pratt and Ching-Hon Pui

Oncogenic Potential of Anticancer Agents 28
Drug Induced Secondary Cancers 29
Assessing the Risk of Second Cancers 29
Contributions of Specific Agents 30
Therapy Related Solid Tumors 31
Therapy Related Leukemia 32
Secondary Leukemia in Acute Leukemia 35
The Future 37
References 37
Chapter 4: Toxicity of Alkylating Agents: Clinical Characteristics and Pharmacokinetic Determinants

David R. Newell and Martin E. Gore

Introduction 44
Specific Agents 45
Gonadal Dysfunction 55
Conclusions 55
References 56

Chapter 5: Toxicity of Antimetabolites

David J. Sweeny and Robert B. Diasio

Introduction 63
Antifolates 63
Pyrimidine Analogs 68
Purine Analogs 75
Summary 77
References 78

Chapter 6: Toxicity of Platinum-Based Anticancer Drugs

Miles P. Hacker

Historical Perspective 82
Mechanism of Action 82
Toxicities 83
References 97

Chapter 7: Toxicity of Free Radical Forming Anticancer Agents

Garth Powis

Introduction 106
 Anthracyclines 106
 Mitoxantrone 124
 Bleomycin 125
 Neocarzinostatin 130
 Conclusions 131
 References 132

Chapter 8: Toxicity of Vinca Alkaloids

Miles P. Hacker

Introduction 152
Vincristine 152
Vinblastine 157
Vindesine 159
Navelbine 160
References 160
## Chapter 9: Immunologic Effects of Cancer Chemotherapy

*Larry D. Grant, Paul R. Kaesberg, and William B. Ershler*

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbreviations</td>
<td>167</td>
</tr>
<tr>
<td>Introduction</td>
<td>167</td>
</tr>
<tr>
<td>Alkylating Agents: Cyclophosphamide</td>
<td>169</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>172</td>
</tr>
<tr>
<td>Antimetabolites: Methotrexate</td>
<td>175</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>177</td>
</tr>
<tr>
<td>5-Fluorouracil (5-FU)</td>
<td>179</td>
</tr>
<tr>
<td>Vinca Alkaloids</td>
<td>180</td>
</tr>
<tr>
<td>Anthracycline Antibiotics</td>
<td>182</td>
</tr>
<tr>
<td>Bleomycin</td>
<td>184</td>
</tr>
<tr>
<td>Cisplatin</td>
<td>185</td>
</tr>
<tr>
<td>References</td>
<td>187</td>
</tr>
</tbody>
</table>

## Chapter 10: Toxicity of Biological Response Modifiers

*Garth Powis and Miles P. Hacker*

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>198</td>
</tr>
<tr>
<td>Interferons</td>
<td>198</td>
</tr>
<tr>
<td>Tumor Necrosis Factor</td>
<td>203</td>
</tr>
<tr>
<td>Interleukin-2</td>
<td>205</td>
</tr>
<tr>
<td>References</td>
<td>208</td>
</tr>
</tbody>
</table>

Index                                                    217